Last reviewed · How we verify
Exendin-4 Fc fusion protein injection
Exendin-4 Fc fusion protein injection is a GLP-1 receptor agonist Small molecule drug developed by Beijing Dongfang Biotech Co., Ltd.. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: JY09(1.2mg), JY09(2.4mg).
Exendin-4 Fc fusion protein activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon in response to elevated blood glucose.
Exendin-4 Fc fusion protein activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Exendin-4 Fc fusion protein injection |
|---|---|
| Also known as | JY09(1.2mg), JY09(2.4mg) |
| Sponsor | Beijing Dongfang Biotech Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Exendin-4 is a GLP-1 receptor agonist derived from Gila monster venom, fused to an Fc domain to extend its half-life. It mimics glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, while simultaneously inhibiting glucagon release and slowing gastric emptying. The Fc fusion increases circulating half-life, allowing for less frequent dosing compared to native exendin-4.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Injection site reactions
Key clinical trials
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients (PHASE3)
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (PHASE3)
- Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exendin-4 Fc fusion protein injection CI brief — competitive landscape report
- Exendin-4 Fc fusion protein injection updates RSS · CI watch RSS
- Beijing Dongfang Biotech Co., Ltd. portfolio CI
Frequently asked questions about Exendin-4 Fc fusion protein injection
What is Exendin-4 Fc fusion protein injection?
How does Exendin-4 Fc fusion protein injection work?
What is Exendin-4 Fc fusion protein injection used for?
Who makes Exendin-4 Fc fusion protein injection?
Is Exendin-4 Fc fusion protein injection also known as anything else?
What drug class is Exendin-4 Fc fusion protein injection in?
What development phase is Exendin-4 Fc fusion protein injection in?
What are the side effects of Exendin-4 Fc fusion protein injection?
What does Exendin-4 Fc fusion protein injection target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Beijing Dongfang Biotech Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: JY09(1.2mg), JY09(2.4mg)
- Compare: Exendin-4 Fc fusion protein injection vs similar drugs
- Pricing: Exendin-4 Fc fusion protein injection cost, discount & access